Anavex Presents Data on Neuroprotective Evidence for ANAVEX 2-73, Lead Compound for Alzheimer’s Disease

Hoboken, NJ — July 26, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.” Neuroprotective, anti-amnesic, anti-depressive…

Anavex Presents Data on Potential Dual Utility of ANAVEX 2-73 in Both Amyloid and Tau Pathology

Hoboken, NJ — July 25, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “The novel aminotetrahydrofuran derivative ANAVEX 2-73 attenuated GSK-3beta and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model…

Anavex to Present at Alzheimer’s Association International Conference on Alzheimer’s Disease

Hoboken, NJ — July 15, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzheimer’s Association International Conference on Alzheimer’s Disease (AAICAD) in…

Anavex Raises $1.575 million

Hoboken, NJ — July 11, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to announce that it has raised $1,575,000 through the exercise of warrants.  Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease, to advance other compounds in…